文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急诊就诊全国概率样本中苯二氮䓬类与阿片类联合处方情况

Benzodiazepine-opioid co-prescribing in a national probability sample of ED encounters.
PubMed 文献 · Am J Emerg Med · 2016-12-02
一句话结论2006至2012年间,开具阿片类处方的急诊就诊中约2.7%同时开具苯二氮䓬类,复诊及精神障碍或肌肉骨骼问题诊断者联合处方 odds 更高。

该研究为美国国家医院门诊医疗护理调查数据的二次分析,使用样本权重估算人群水平,描述2006至2012年急诊苯二氮䓬类-阿片类联合处方的年度患病率,并用多变量逻辑回归比较联合处方与单用阿片类处方的急诊就诊特征。结果显示联合处方患病率在此期间无显著变化,所有开具阿片类处方的急诊就诊中2.7%(95%CI 2.5-2.8%)同时开具苯二氮䓬类。与单用阿片类处方的就诊相比,联合处方就诊更可能是复诊而非初诊(OR 1.52)、接受更多药物(OR 1.41)和更少操作(OR 0.48),更可能有精神障碍相关诊断(OR 20.60)或肌肉骨骼问题诊断(OR 3.71)。

要点

  • 2006至2012年,开具阿片类处方的急诊就诊中2.7%(95%CI 2.5-2.8%)同时开具苯二氮䓬类,联合处方患病率在此期间无显著变化。
  • 与单用阿片类处方的急诊就诊相比,联合处方就诊更可能是复诊而非初诊(OR 1.52)。
  • 联合处方就诊更可能有精神障碍相关诊断(OR 20.60)或肌肉骨骼问题诊断(OR 3.71)。
  • 联合处方就诊接受更多药物(OR 1.41)和更少操作(OR 0.48)。

适用人群与场景

  • 2006至2012年美国国家医院门诊医疗护理调查中开具阿片类处方的急诊就诊。

研究设计与关键结果

  • 研究类型为美国国家医院门诊医疗护理调查数据的二次分析,使用样本权重估算人群水平。
  • 主要目标为描述2006至2012年急诊苯二氮䓬类-阿片类联合处方的年度患病率,使用95%置信区间比较相邻年份。
  • 联合处方患病率从2006至2012年无显著变化。
  • 期间开具阿片类处方的急诊就诊中2.7%(95%CI 2.5-2.8%)同时开具苯二氮䓬类。
  • 与单用阿片类处方的就诊相比,联合处方就诊更可能是复诊而非初诊(OR 1.52)。
  • 联合处方就诊接受更多药物(OR 1.41)和更少操作(OR 0.48)。
  • 联合处方就诊更可能有精神障碍相关诊断(OR 20.60)或肌肉骨骼问题诊断(OR 3.71)。

证据类型、等级与局限

  • 证据类型为基于全国概率样本的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression, and the rate of death due to benzodiazepine-opioid overdose is increasing. Little is known about the prevalence and characteristics of benzodiazepine-opioid co-prescribing from the ED setting.

METHODS: Secondary analysis of data from the National Hospital Ambulatory Medical Care Survey, using sample weights to generate population estimates. The primary objective was to describe the annual prevalence of benzodiazepine-opioid co-prescribing from 2006 to 2012, using 95% confidence intervals (95% CI) to compare adjacent years. The secondary objective was to compare characteristics of ED encounters receiving a benzodiazepine-opioid co-prescription versus those receiving an opioid prescription alone, using a multivariable logistic regression.

RESULTS: The prevalence of benzodiazepine-opioid co-prescribing did not significantly change from 2006 to 2012. During this period, 2.7% (95% CI: 2.5-2.8%) of ED encounters prescribed an opioid were also prescribed a benzodiazepine. Relative to encounters receiving an opioid prescription alone, encounters receiving a co-prescription were more likely to represent a follow-up rather than initial visit (Odds Ratio [OR] 1.52), receive more medications (OR 1.41) and fewer procedures (OR 0.48) while in the ED, and more likely to have a diagnosis related to mental disorder (OR 20.60) or musculoskeletal problem (OR 3.71).

CONCLUSIONS: From 2006 to 2012, almost 3% of all ED encounters receiving an opioid prescription also received a benzodiazepine co-prescription. The odds of benzodiazepine-opioid co-prescribing were significantly higher in ED encounters representing a follow-up visit and in diagnoses relating to a mental disorder or musculoskeletal problem.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kim HS, McCarthy DM, Mark Courtney D, et al. Benzodiazepine-opioid co-prescribing in a national probability sample of ED encounters. Am J Emerg Med. 2016. PMID: 27923527. doi:10.1016/j.ajem.2016.11.054

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。